Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

LGND Stock Annual Income Statement. Download in Excel

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

Sector: Healthcare   

Industry: Biotechnology

114.64
 
USD
  
0.70
  
(0.61%)
Previous close: 113.945  Open: 112.06  Bid: 50.47  Ask: 134.0
52 week range    
67.53   
   129.90
Mkt Cap: 2,276 M  Avg Vol (90 Days): 155,331
Peers   
AMGN / 
SPPI / 
GSK / 
MRK / 
PFE / 
LLY / 
BMY / 
BAX / 
Last updated: Monday 23rd December 2024

Stock Rankings

52
MarketXLS Rank
60
Value
46
Technical
50
Quality
How are these ranks calculated?
Search for a stock

Financials

LGND Income Statement

Annual
Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22Dec-23
Amortization of intangibles-2 M-2 M-11 M-11 M-16 M210 M595 M34 M106 M103 M
Basic EPS from continuing operations0.378.11-0.070.374.2220.67-0.112.15-0.313.11
Basic EPS total20.67-0.112.15-1.983.02
Basic weighted shares outstanding33 M32 M33 M34 M34 M30 M26 M27 M17 M17 M
BasicDiscontinuousOperations0.02-1.67-0.1
CommissionExpenses47 M34 M
Cost of sales-9 M-6 M-6 M-5 M6 M11 M30 M62 M53 M11 M
Depreciation-300000.0-200000.0-200000.0-400000.0-900000.02 M2 M2 M4 M3 M
Depreciation unreconciled2 M11 M12 M16 M23 M34 M
DepreciationAndAmortization-300000.02 M11 M12 M16 M2 M2 M34 M4 M3 M
Diluted EPS total19.87-0.112.06-1.982.94
Diluted normalized net income/share0.357.56-0.070.333.7219.87-0.112.06-0.313.03
Diluted weighted shares outstanding34 M34 M33 M38 M39 M32 M26 M28 M17 M18 M
DilutedDiscontinuousOperations0.02-1.67-0.09
Earnings from equity interest-5 M-23 M-2 M
EarningsFromEquityInterestNetOfTax-5 M-23 M-2 M
ExciseTaxes17 M
GainOnSaleOfBusiness1 M2 M
GainOnSaleOfSecurity5 M28 M12000.050 M1 M-17 M-5 M29 M47 M
GainsLossOnDisposalOfDiscontinuedOperations731000.0
GeneralAndAdministrativeExpense23 M24 M28 M29 M38 M42 M64 M47 M70 M53 M
Gross operating profit55 M66 M103 M136 M245 M109 M133 M179 M143 M121 M
ImpairmentOfCapitalAssets16000.017 M
Income before tax11 M35 M8 M57 M173 M797 M-11 M72 M36 M64 M
Income restructuring and M&A1 M1 M1 M
Income taxes410000.0-192 M10 M45 M30 M167 M-5 M-4 M41 M10 M
Interest income14 M28 M8 M886000.02 M8 M
InterestExpenseNonOperating778000.013 M48 M36 M27 M20 M2 M656000.0
MarketingExpense23 M
MinorityInterests1 M2 M767 M
MiscOtherSpecialCharges2 M2 M3 M3 M-6 M809 M17 M-8 M4 M-2 M
Net income from total operations12 M230 M-3 M13 M143 M629 M-3 M57 M-33 M52 M
NetIncomeCommonStockholders12 M230 M-3 M13 M143 M629 M-3 M57 M-33 M52 M
NetIncomeContinuousOperations12 M230 M-3 M13 M143 M629 M-3 M57 M-5 M54 M
NetIncomeDiscontinuousOperations731000.0-19 M-28 M-2 M
NetIncomeExtraordinary-2 M13 M
NetNonOperatingInterestIncomeExpense-778000.0-13 M-34 M-7 M-19 M-19 M247000.07 M
NetOperatingInterestIncomeExpense-5 M-12 M-12 M-11 M
Operating income21 M28 M44 M68 M164 M807 M26 M104 M3 M12 M
Operating income before depreciation (EBITDA)18 M48 M31 M94 M275 M896 M57 M143 M89 M100 M
OperatingExpense-45 M-45 M-65 M-73 M-88 M126 M178 M138 M140 M111 M
Other income net3 M-20 M24 M-3 M-44 M-810 M-73000.013 M33 M47 M
Other special charges-38 M
OtherGainLossFromDispositionOfDiscontinuedOperations-19 M-28 M-2 M
OtherGandA23 M24 M28 M29 M38 M42 M64 M47 M70 M53 M
OtherOperatingExpenses-40000.0-154000.0-70000.0-1 M-1 M-543000.0-4 M-38 M-58000.0-47000.0
OtherWriteOff300000.0-200000.0
RentAndLandingFees23 M24 M28 M29 M38 M
Research & development expense12 M11 M21 M27 M28 M56 M59 M32 M36 M25 M
ResearchExpense12 M11 M21 M27 M28 M56 M59 M32 M36 M25 M
RestructringAndMnAIncome1 M1 M1 M
Revenue per share-2 M2 M11 M12 M16 M210 M595 M34 M140 M137 M
SalariesAndWages-11 M-12 M-19 M-25 M-21 M25 M31 M29 M51 M26 M
SecuritiesAmortization34 M
Selling Gen & administrative expense23 M24 M28 M29 M38 M42 M88 M47 M104 M53 M
SellingAndMarketingExpense23 M47 M34 M
Special income/charges-1 M-1 M-1 M-17 M38 M
Total Income available for interest expense (EBIT)12 M35 M8 M71 M222 M832 M29 M92 M38 M64 M
Total common shares outstanding31 M33 M34 M34 M33 M26 M27 M27 M17 M18 M
Total net income12 M230 M-3 M13 M143 M629 M-3 M57 M-33 M52 M
Total ordinary shares19 M19 M19 M19 M19 M19 M19 M19 M19 M19 M
Total revenues65 M72 M109 M141 M251 M120 M186 M242 M196 M131 M
TotalExpenses-54 M-50 M-71 M-78 M-81 M137 M208 M200 M193 M121 M
TotalRevenue28 M28 M23 M141 M251 M120 M164 M242 M196 M131 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University